Insilico Medicine (03696) has announced that the company has entered into a strategic collaboration agreement with Takeda Pharmaceutical Co Ltd (TAK).

The partnership will leverage Insilico's proprietary end-to-end Pharma.AI platform to advance the discovery of candidate drugs in selected therapeutic areas chosen by Takeda. The goal of the collaboration is to identify novel drug candidates with potential for clinical differentiation by targeting high-potential therapeutic targets.

Under the terms of the agreement, Insilico will lead the AI-driven drug discovery efforts, responsible for identifying candidate molecules meeting predefined scientific and early-development criteria. Takeda will contribute its extensive global development capabilities to advance the clinical validation of the resulting candidate drugs.

Financially, Insilico is set to receive approximately $60 million in upfront and near-term milestone payments. The company is also eligible for additional milestone payments tied to preclinical, clinical, commercial, and sales progress, with the total potential deal value reaching up to approximately $600 million. Furthermore, Insilico is entitled to receive tiered royalty payments based on future net sales following the commercialization of any products.

In return, Takeda will secure exclusive global rights for the development, manufacturing, and commercialization of any novel therapies discovered through this collaboration.